Evidence map›Paper›PMID 24518818›Full record

ArticleEpigenetics2014

CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas.

Lifeng Sun, Angela A Guzzetta, Tao Fu, Jinming Chen, Jana Jeschke, Ruby Kwak, Rajita Vatapalli, Stephen B Baylin, Christine A Iacobuzio-Donahue, Christopher L Wolfgang and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Case series of non-ampullary duodenal adenomas.Annals of medicine and surgery (2012) · 2021
    Article
  2. Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations.International journal of molecular sciences · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Lifeng SunDepartment of Surgical Oncology; Second Affiliated Hospital; Zhejiang University School of Medicine; Hangzhou, PR China; Department of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Angela A GuzzettaDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Tao FuDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Urology; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Gastrointestinal Surgery; Daping Hospital; Third Military Medical University; Chongqing, PR China.
Jinming ChenDepartment of Surgical Oncology; Second Affiliated Hospital; Zhejiang University School of Medicine; Hangzhou, PR China; Department of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Jana JeschkeDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Ruby KwakDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Rajita VatapalliDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Stephen B BaylinDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Christine A Iacobuzio-DonahueDepartment of Pathology; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Christopher L WolfgangDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Oncology; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA.
Nita AhujaDepartment of Surgery; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Oncology; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Urology; The Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore, MD USA; Department of Gastrointestinal Surgery; Daping Hospital; Third Military Medical University; Chongqing, PR China.
Sidney Kimmel Comprehensive Cancer Center · USUniversity of Baltimore · USJohns Hopkins Medicine · USJohns Hopkins University · USDaping Hospital · CN

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Epigenetic markers involved in colorectal cancer recurrence and metastasesK23CA127141 · NCI · JOHNS HOPKINS UNIVERSITY · PI AHUJA, NITA · 2008 to 2012
$705k
NCI NIH HHS CA127141NCI NIH HHS K23 CA127141NCI NIH HHS P30 CA006973NCI NIH HHS P30CA006973NCI NIH HHS T32 CA126607NCI NIH HHS T32CA126607
6 · The paper itself

Abstract

CpG island methylator phenotype (CIMP) has been found in multiple precancerous and cancerous lesions, including colorectal adenomas, colorectal cancers, and duodenal adenocarcinomas. There are no reports in the literature of a relationship between CIMP status and clinicopathologic features of sporadic duodenal adenomas. This study sought to elucidate the role of methylation in duodenal adenomas and correlate it with KRAS and BRAF mutations. CIMP+ (with more than 2 markers methylated) was seen in 33.3% of duodenal adenomas; 61% of these CIMP+ adenomas were CIMP-high (with more than 3 markers methylated). Furthermore, CIMP+ status significantly correlated with older age of patients, larger size and villous type of tumor, coexistent dysplasia and periampullary location. MLH1 methylation was seen in 11.1% of duodenal adenomas and was significantly associated with CIMP+ tumors, while p16 methylation was an infrequent event. KRAS mutations were frequent and seen in 26.3% of adenomas; however, no BRAF mutations were detected. Furthermore, CIMP-high status was associated with larger size and villous type of tumor and race (non-white). These results suggest that CIMP+ duodenal adenomas may have a higher risk for developing malignancy and may require more aggressive management and surveillance.

Indexed as

CpG IslandsDNA MethylationAdenomaColorectal NeoplasmsEpigenesis, GeneticFemaleGenes, p16HumansMaleMiddle AgedPhenotypeProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsRiskBRAF protein, humanKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteinsampullary adenomasCpG island methylator phenotypeDNA methylationgastrointestinal tumorssporadic duodenal adenomas

Identifiers

PMID24518818
PMCPMC4063833
OpenAlexW1978850955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.